Correlation of Activated Clotting Time (ACT) with rFVIIa Infusion and Clinical Efficacy in a Patient with Glanzmann Thrombasthenia and Platelet Alloantibodies

Thromb Haemost 2002; 87(06): 1084
DOI: 10.1055/s-0037-1613141

Letters to the Editor

Schattauer GmbH

Afshin Ameri

¹Division of Pediatric Hematology/Oncology, University of Louisville; Novo Nordisk Pharmaceuticals, Inc., USA

,

Scott Stolte

¹Division of Pediatric Hematology/Oncology, University of Louisville; Novo Nordisk Pharmaceuticals, Inc., USA

References
1 George JN, Caen JP, Nurden AT. Glanzmann’s thrombasthenia: the spectrum of clinical disease. Blood 1990; 75: 1383-95.
2 Bierhng P, Fromont P, Elbez A, Duedari N, Kieffer N. Early immunization against platelet glycoprotein IIIa in a newborn Glanzmann type I patient. Vox Sanguinis 1998; 55: 109-13.
3 Ito K. et al. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann’s thrombasthenia and multiple anti-platelet antibodies. Vox Sanguinis 1991; 61: 40-6.
4 Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94: 3951-3.